2009•Chinese Journal of OsteoporosisRequires access

Progress in osteoprotegerin prevention and therapy for osteoporosis

Hou Jiaf

Open publisher page 0 citations

Abstract

Osteoprotegerin(OPG),receptor activator of NF-κB ligand(RANKL),receptor activator of NF-κB(RANK) are important factors in modulating bone resorption and formation.Osteoporosis is the result of many reasons that activate osteoclasts and destroy bone dynamic balance.OPG,which competes with RANK,binds with RANKL,inhibits osteoclast differentiation and activation and promotes osteoclast apoptosis.Recombinated OPG protein and OPG gene therapy are the most promising method that prevent and treat osteoporosis.The current status of recombination OPG protein and OPG gene therapy for osteoporosis was reviewed briefly in this article.

About this research paper

What this paper is about

Osteoprotegerin(OPG),receptor activator of NF-κB ligand(RANKL),receptor activator of NF-κB(RANK) are important factors in modulating bone resorption and formation.Osteoporosis is the result of many reasons that activate osteoclasts and destroy bone dynamic balance.OPG,which competes with RANK,binds with RANKL,inhibits osteoclast differentiation and activation and promotes osteoclast apoptosis.Recombinated OPG protein and OPG gene therapy are the most promising method that prevent and treat osteoporosis.The current status of recombination OPG protein and OPG gene therapy for osteoporosis was reviewed briefly in this article.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Osteoprotegerin(OPG),receptor activator of NF-κB ligand(RANKL),receptor activator of NF-κB(RANK) are important factors in modulating bone resorption and formation.Osteoporosis is the result of many reasons that activate osteoclasts and destroy bone dynamic balance.OPG,which competes with RANK,binds with RANKL,inhibits osteoclast differentiation and activation and promotes osteoclast apoptosis.Recombinated OPG protein and OPG gene therapy are the most promising method that prevent and treat osteoporosis.The current status of recombination OPG protein and OPG gene therapy for osteoporosis was reviewed briefly in this article.

Key concepts: Osteoprotegerin, RANKL, Osteoclast, Osteoporosis, Activator (genetics), Bone resorption, Medicine, Receptor

Related papers

Back to paper searchBrowse research topicsOriginal source
Progress in osteoprotegerin prevention and therapy for osteoporosis — Research Paper | ScholarLens